AstraZeneca plc (LON:AZN) has been assigned a GBX 4,900 ($63.28) target price by analysts at Jefferies Group LLC in a report released on Monday. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s target price would suggest a potential upside of 3.82% from the company’s previous close.

Several other analysts have also commented on AZN. Deutsche Bank AG reissued a “buy” rating on shares of AstraZeneca plc in a research report on Monday, May 22nd. Shore Capital reissued a “hold” rating on shares of AstraZeneca plc in a research report on Tuesday, May 23rd. Liberum Capital reissued a “buy” rating and set a GBX 5,500 ($71.03) price target on shares of AstraZeneca plc in a research report on Tuesday, May 23rd. J P Morgan Chase & Co reissued a “neutral” rating and set a GBX 4,500 ($58.12) price target on shares of AstraZeneca plc in a research report on Tuesday, May 23rd. Finally, Goldman Sachs Group, Inc. (The) reissued a “sell” rating and set a GBX 3,900 ($50.37) price target on shares of AstraZeneca plc in a research report on Friday, May 26th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the company’s stock. AstraZeneca plc presently has a consensus rating of “Hold” and a consensus target price of GBX 5,027.45 ($64.93).

Shares of AstraZeneca plc (AZN) opened at 4694.00 on Monday. The firm’s 50-day moving average is GBX 4,556.15 and its 200-day moving average is GBX 4,880.61. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00. The company’s market capitalization is GBX 59.43 billion.

WARNING: “AstraZeneca plc (AZN) PT Set at GBX 4,900 by Jefferies Group LLC” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/09/18/astrazeneca-plc-azn-pt-set-at-gbx-4900-by-jefferies-group-llc.html.

In other AstraZeneca plc news, insider Nazneen Rahman purchased 39 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.